Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ADR ARGX

Healthcare Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an... see more

Recent & Breaking News (NDAQ:ARGX)

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

GlobeNewswire September 15, 2023

argenx to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2023

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

GlobeNewswire July 27, 2023

argenx announces closing of global offering

GlobeNewswire July 24, 2023

argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

GlobeNewswire July 20, 2023

argenx announces full exercise of underwriters' option to purchase additional ADSs

GlobeNewswire July 19, 2023

argenx raises $1.1 billion in gross proceeds in a global offering

GlobeNewswire July 18, 2023

argenx announces launch of proposed global offering

GlobeNewswire July 17, 2023

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

GlobeNewswire July 17, 2023

argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

GlobeNewswire July 17, 2023

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

GlobeNewswire June 30, 2023

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

GlobeNewswire June 30, 2023

argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis

GlobeNewswire June 20, 2023

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

GlobeNewswire June 20, 2023

argenx to Present at Upcoming Investor Conferences

GlobeNewswire May 31, 2023

argenx Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 4, 2023

argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire May 3, 2023

argenx to Present at BofA Securities 2023 Health Care Conference

GlobeNewswire May 2, 2023

argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

GlobeNewswire April 27, 2023

argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting

GlobeNewswire April 18, 2023